Bisphosphonate Choice as Adjuvant Therapy for Breast Cancer: Does it Matter?

J Natl Cancer Inst. 2020 Jul 1;112(7):659-660. doi: 10.1093/jnci/djz216.

Authors

Adam Brufsky¹, Aju Mathew²

Affiliations

¹ UPMC Hillman Cancer Center, Magee-Women's Hospital, Pittsburgh, PA.
² Welcare Hospital, Kochi, & MOSC Medical College, Kolenchery, Kerala, India.

No abstract available

Publication types

Editorial
Comment

MeSH terms

Bone Density Conservation Agents* / therapeutic use
Breast Neoplasms* / drug therapy
Chemotherapy, Adjuvant
Combined Modality Therapy
Diphosphonates / therapeutic use
Humans

Substances

Bone Density Conservation Agents
Diphosphonates